Rib-X Pharmaceuticals, Inc. (”Rib-X” or the “Company”), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced the initiation of a Phase 2 clinical trial for an intravenous form of antibiotic compound RX-3341 in the treatment of complicated skin and skin structure infections (cSSSIs). The safety and efficacy study will be conducted at 35 sites across the United States.

This post is an original post by ScienceDaily: Skin Care News

Posted: July 16th, 2008 under skin health.
Comments: none